Form 4: Kymera Therapeutics CFO Sells Shares

Kymera Therapeutics' Chief Financial Officer, Bruce N. Jacobs, reported transactions involving the sale of common stock and the acquisition of stock options on June 30, 2026, executed under a Rule 10b5-1 trading plan.

Summary

• Bruce N. Jacobs, Chief Financial Officer of Kymera Therapeutics, Inc., engaged in stock transactions on June 30, 2026.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan.
• Jacobs acquired 61,378 shares of common stock at a price of $5.33 per share.
• He also disposed of a total of 61,375 shares of common stock through multiple sales at prices ranging from $110.37 to $118.09.
• Following these transactions, Jacobs beneficially owns 244,883 shares of common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the significant sale of shares by a key executive, despite the use of a 10b5-1 plan. The acquisition of shares at a much lower price alongside the sales suggests a potential divergence in perceived value.

Positives

• The acquisition of 61,378 shares at a lower price ($5.33) could represent a favorable entry point for the CFO.
• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially non-insider trading activity.

Negatives

• The disposal of a significant number of shares (61,375) at prices substantially higher than the acquisition price suggests profit-taking by a key executive.
• The weighted average sale price of approximately $114.77 indicates a substantial gain on the disposed shares.

Risks

• Potential for negative market perception due to a large volume of stock sales by a senior executive, even if conducted under a 10b5-1 plan.
• The significant difference between the acquisition price of new shares and the sale price of existing shares could be interpreted as a sign of overvaluation by management.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• Transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026, adopted by the reporting person.
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported ranges upon request.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine for executives and directors, detailing changes in their beneficial ownership. The use of a Rule 10b5-1 plan is a common strategy to manage stock sales while adhering to insider trading regulations, particularly relevant in the biotechnology sector where stock prices can be volatile.

Stakeholder Impact

• Shareholders may view the significant sale of shares by the CFO with caution, potentially impacting short-term stock price sentiment.
• Employees may interpret the CFO's stock sales as a signal regarding the company's short-term prospects, although the 10b5-1 plan mitigates direct insider trading concerns.

Next Steps

• The reporting person may be required to provide further information regarding the specific prices of shares sold upon request from the SEC, the Issuer, or any security holder.

Key Dates

Recommendation

The filing reports routine stock transactions by an executive under a pre-established plan. While the sale of a significant number of shares could be a short-term negative signal, the acquisition of shares at a much lower price and the adherence to a 10b5-1 plan suggest a balanced approach. Without further financial or strategic information, a 'hold' recommendation is prudent, pending a broader analysis of the company's performance and outlook.

Keywords

Form 4, Insider Trading, Stock Sale, Stock Option, Rule 10b5-1, Kymera Therapeutics, KYMR, Bruce N. Jacobs, Beneficial Ownership, Securities Exchange Act